Merck KGaA verhandelt Milliardendeal mit US-Tumorspezialisten
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon
Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares following the Food and Drug Administration’s approval for Gomekli ...
FiercePharma2d
UPDATE: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
devdiscourse1d
Merck Foundation Champions Girl Education and Women's Empowerment
Merck Foundation, led by CEO Senator Dr. Rasha Kelej, is dedicated to empowering women and youth in science and education in ...
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...
SpringWorks shares up 39% to $55.90 after Merck KGaA confirms talks
EST SpringWorks shares up 39% to $55.90 after Merck KGaA (MKGAY) confirms talksMaximize Your Portfolio with Data Driven Insights:Leverage ...
devdiscourse2d
Merck's Ambitious Pursuit of SpringWorks: A Strategic Bet in Oncology
Merck KGaA is in advanced talks to acquire SpringWorks Therapeutics, aiming to expand its cancer treatment pipeline. While no binding agreement exists yet, a potential deal is seen as strategically ...